One biotechnology player that insiders are jumping into big here is Synta Pharmaceuticals (SNTA), which focuses on the discovery, development and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. Insiders are buying this stock into major weakness, since shares are down by 39% so far in 2014.
Synta Pharmaceuticals has a market cap of $342 million and an enterprise value of $273 million. This stock trades at a premium valuation, with a price-to-book of 7.10. Its estimated growth rate for this year is 8.7%, and for next year it's pegged at -6%. This is a cash-rich company, since the total cash position on its balance sheet is $91.48 million and its total debt is $23.40 million.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts